Bio-Techne invests $257M for 20% of Wilson Wolf; future buyout up to $1B

BIO-TECHNE Corp

Wilson Wolf met trailing 12-month EBITDA target of $55M, triggering Bio-Techne's option.
Bio-Techne will pay $257M for a 20% ownership stake; close expected end of March 2023.
Remaining 80% can be acquired for $1B if Wilson Wolf hits $226M revenue or $136M EBITDA.
If milestone not met by Dec 31, 2027, Bio-Techne can buy for ~4.4x trailing revenue.
Wilson Wolf's G-Rex cell production tech is used by over 800 cell and gene therapy entities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.